Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of saRNA Influenza Vaccines in Healthy Individuals
NCT05227001Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Vaccine mRNA, mRNA Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07852352, PF-07836391, PF-07836394, PF-07836395, PF-07871987 and 1 more in influenza (26 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions at 10 days, Percentage of participants reporting systemic events at 10 days and 5 more. Started Apr 2022; status: completed.
02
Drugs
PF-07852352PF-07836391PF-07836394PF-07836395PF-07871987
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05227001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227001.